Wedbush Expects Increased Earnings for Larimar Therapeutics

Key Points

• Analysts at Wedbush have increased their Q3 2025 EPS forecast for Larimar Therapeutics from ($0.41) to ($0.33), maintaining an "Outperform" rating with a target price of $15.00.
• The company's latest earnings report showed a loss of ($0.41) per share, surpassing expectations of ($0.47).
• Insider activity is notable, with Director James E. Flynn acquiring 9,375,000 shares at an average price of $3.20, significantly increasing his stake in the company.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Research analysts at Wedbush boosted their Q3 2025 earnings per share estimates for Larimar Therapeutics in a report issued on Thursday, August 14th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.33) for the quarter, up from their prior estimate of ($0.41). Wedbush has a "Outperform" rating and a $15.00 price target on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics' Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.53) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.51) EPS, FY2027 earnings at ($1.21) EPS and FY2029 earnings at $2.76 EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.06.

A number of other research firms also recently weighed in on LRMR. JMP Securities dropped their price target on shares of Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating for the company in a research report on Friday, August 15th. Guggenheim reissued a "buy" rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Finally, Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. One research analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $18.43.

Larimar Therapeutics Trading Up 6.0%

Shares of NASDAQ:LRMR traded up $0.22 during trading on Monday, reaching $3.91. 1,421,476 shares of the stock were exchanged, compared to its average volume of 1,828,442. Larimar Therapeutics has a 12 month low of $1.61 and a 12 month high of $9.50. The firm has a market cap of $323.67 million, a PE ratio of -2.51 and a beta of 0.93. The stock has a 50-day moving average price of $3.38 and a 200-day moving average price of $2.79.

Insider Activity

In related news, Director James E. Flynn purchased 9,375,000 shares of the firm's stock in a transaction dated Thursday, July 31st. The stock was bought at an average price of $3.20 per share, for a total transaction of $30,000,000.00. Following the purchase, the director directly owned 9,538,945 shares in the company, valued at approximately $30,524,624. This trade represents a 5,718.38% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets bought a new position in Larimar Therapeutics in the 4th quarter worth approximately $25,000. Algert Global LLC bought a new stake in Larimar Therapeutics in the fourth quarter worth $47,000. Savant Capital LLC bought a new stake in Larimar Therapeutics in the second quarter valued at approximately $39,000. Wealth Enhancement Advisory Services LLC bought a new stake in Larimar Therapeutics in the second quarter valued at approximately $44,000. Finally, Graham Capital Management L.P. bought a new position in shares of Larimar Therapeutics during the fourth quarter valued at about $54,000. 91.92% of the stock is owned by institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.